VANCOUVER, British Columbia, June 17, 2011 /PRNewswire/ -- Abattis Biologix Corporation (CNSX: FLU) announced today that their shares have commenced trading on the OTC Pink Sheets under the symbol ABBTF. Pink Sheet trading will provide shareholders with liquidity as the company proceeds with financing activities and the preparation of additional disclosure documents for listing on higher tier OTC platforms and other exchanges.
Mike Withrow, CEO of Abattis stated, "This is the first in three steps toward becoming a fully reporting issuer with the SEC. The company is fully reporting in Canada and is in the process of converting to IFRS. It will provide transparency about our company in both countries and better access to its stock in the US, which will attract new investors and expand our stockholder base."
"We continue to strengthen our IP and are preparing to launch our portfolio of proprietary products into strategic distribution channels. Shareholders and investors should expect to see additional news releases in the coming weeks on these and other events and activities as we move toward that goal," added Withrow.
About Abattis Biologix Corp.
Abattis Biologix Corporation is committed to the research, development and marketing of proprietary natural health and wellness solutions that address chronic illnesses through targeted nutritional support. We manufacture and market the most scientifically advanced natural therapeutic formulas based on proprietary technologies through multiple distribution channels, while providing the highest level of customer service.
Web: www.abattis.com Twitter:@abattis
Safe Harbor Statement: This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated.
916 220 3500
Investor Relations Contact:
604 828 8600
|SOURCE Abattis Biologix Corporation|
Copyright©2010 PR Newswire.
All rights reserved